Print Page     Close Window     

SEC Filings

10-K/A
BIOTIME INC filed this Form 10-K/A on 04/02/2018
Entire Document
 
 

 

ONCOCYTE CORPORATION

STATEMENTS OF OPERATIONS

(In thousands, except per share data)

 

   Year Ended December 31, 
   2017   2016   2015 
             
OPERATING EXPENSES               
Research and development  $7,174   $5,677   $4,527 
General and administrative   9,232    4,265    3,867 
Sales and marketing   2,443    1,198    324 
Total operating expenses   18,849    11,140    8,718 
                
Loss from operations   (18,849)   (11,140)   (8,718)
                
OTHER EXPENSES, NET               
Loss on sale of available-for-sale securities and other expenses, net   (309)   -    - 
Interest expense, net   (217)   (28)   (19)
Other income, net   -    -    2 
Total other expenses, net   (526)   (28)   (17)
                
NET LOSS  $(19,375)  $(11,168)  $(8,735)
                
Basic and diluted net loss per share  $(0.64)  $(0.42)  $(0.42)
                
Weighted average shares outstanding: basic and diluted   30,195    26,529    21,009 

 

The accompanying notes are an integral part of these financial statements.

 

   

© Copyright BioTime, Inc.